U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 001-38758

Enochian Biosciences Inc.

(Exact name of registrant as specified in its charter)

Delaware		45-2559340
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

1927 Paseo Rancho Castillo Los Angeles, CA		90032
(Address of principal executive offices)		(Zip Code)

+1(305) 918-1980

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		ENOB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 9, 2023, the number of shares of the registrant’s common stock outstanding was 55,705,521.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

- INDEX -

		Page
PART I – FINANCIAL INFORMATION:		1

Item 1.	Financial Statements (Unaudited):	1

	Condensed Consolidated Balance Sheets as of December 31, 2022 (Unaudited) and June 30, 2022	2

	Condensed Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2022, and 2021 (Unaudited)	3

	Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended December 31, 2022, and 2021 (Unaudited)	4

	Condensed Consolidated Statements of Stockholders’ Equity for the Six Months Ended December 31, 2022, and 2021 (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2022, and 2021 (Unaudited)	7

	Notes to the Condensed Consolidated Financial Statements (Unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33

Item 4.	Controls and Procedures	33

PART II – OTHER INFORMATION:		34

Item 1.	Legal Proceedings	34

Item 1A.	Risk Factors	35

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35

Item 3.	Defaults Upon Senior Securities	35

Item 4.	Mine Safety Disclosures	35

Item 5.	Other Information	35

Item 6.	Exhibits	35

Signatures		36

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

The results for the periods ended December 31, 2022, are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Form 10-K for the fiscal year ended June 30, 2022, filed with the Securities and Exchange Commission on February 27, 2023.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


	December 31,			June 30,
	2022			2022
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	4,118,896		$	9,172,142
Prepaids and other assets		1,270,575			392,996
Total Current Assets		5,389,471			9,565,138

Property and equipment, net		555,916			586,536

OTHER ASSETS:
Definite life intangible assets, net		42,084			44,268
Indefinite life intangible assets, net		61,571,000			61,571,000
Goodwill		11,640,000			11,640,000
Deposits and other assets		61,936			68,635
Operating lease right-of-use assets		1,013,256			1,157,086
Total Other Assets		74,328,276			74,480,989

TOTAL ASSETS	$	80,273,663		$	84,632,663

LIABILITIES
CURRENT LIABILITIES:
Accounts payable – trade	$	4,555,226		$	1,401,867
Accrued expenses		932,603			1,031,462
Other current liabilities		875,415			220,685
Contingent consideration liability		—			2,343,318
Notes payable, net		4,726,390			—
Convertible notes payable		—			1,200,000
Current portion of operating lease liabilities		202,370			253,636
Total Current Liabilities		11,292,004			6,450,968

NON-CURRENT LIABILITIES:
Convertible notes payable		1,200,000			—
Notes payable, net		—			4,577,148
Operating lease liabilities, net of current portion		882,303			985,699
Total Non-Current Liabilities		2,082,303			5,562,847
Total Liabilities		13,374,307			12,013,815

Commitments and Contingencies		—			—

STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, par value $0.0001, 100,000,000 shares authorized, 55,705,521 shares issued and outstanding at December 31, 2022, and 53,007,082 shares issued and outstanding at June 30, 2022		5,572			5,302
Additional paid-in capital		283,426,764			276,989,179
Accumulated deficit		(216,502,705	)		(204,345,197	)
Accumulated other comprehensive loss		(30,275	)		(30,436	)
Total Stockholders’ Equity		66,899,356			72,618,848

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	80,273,663		$	84,632,663

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)


	For the Three Months Ended						For the Six Months Ended
	December 31,						December 31,
	2022			2021			2022			2021

Operating Expenses
General and administrative	$	4,013,063		$	3,961,764		$	8,569,903		$	8,379,268
Research and development		325,959			2,337,222			2,931,334			5,392,658
Depreciation and amortization		28,844			31,805			57,245			63,538
Total Operating Expenses		4,367,866			6,330,791			11,558,482			13,835,464

LOSS FROM OPERATIONS		(4,367,866	)		(6,330,791	)		(11,558,482	)		(13,835,464	)

Other Income (Expense)

Loss on extinguishment of contingent consideration		—			—			(419,182	)		—
Change in fair value of contingent consideration		—			(167,255	)		—			(2,991,897	)
Interest expense		(92,892	)		(93,382	)		(188,477	)		(183,121	)
Gain on currency transactions		—			—			—			9
Interest and other income		3,010			8,487			8,633			15,597
Total Other Income (Expense)		(89,882	)		(252,150	)		(599,026	)		(3,159,412	)

Loss Before Income Taxes		(4,457,748	)		(6,582,941	)		(12,157,508	)		(16,994,876	)

Income Tax (Provision) Benefit		—			—			—			(34	)

NET LOSS	$	(4,457,748	)	$	(6,582,941	)	$	(12,157,508	)	$	(16,994,910	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.08	)	$	(0.13	)	$	(0.22	)	$	(0.33	)

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED		55,509,239			52,321,982			55,304,356			52,270,821

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)


	For the Three Months Ended						For the Six Months Ended
	December 31,						December 31,
	2022			2021			2022			2021

Net Loss	$	(4,457,748	)	$	(6,582,941	)	$	(12,157,508	)	$	(16,994,910	)
Other Comprehensive Income (Loss)
Foreign currency translation, net of taxes		7,915			(3,990	)		161			(7,983	)

Comprehensive Loss	$	(4,449,833	)	$	(6,586,931	)	$	(12,157,347	)	$	(17,002,893	)

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)


	# of Shares		Common Shares		Additional Paid-In Capital		Accumulated Deficit			Accumulated Other Comprehensive Income			Total
July 1, 2022		53,007,082	$	5,302	$	276,989,179	$	(204,345,197	)	$	(30,436	)	$	72,618,848
Stock issued pursuant to warrants exercised		1,250,000		125		1,624,875								1,625,000
Shares issued for earn-out		1,250,000		125		2,762,375								2,762,500
Stock-based compensation		—		—		1,026,008		—			—			1,026,008
Net Loss		—		—		—		(7,699,760	)		—			(7,699,760	)
Foreign currency translation adjustment		—		—		—		—			(7,754	)		(7,754	)
September 30, 2022		55,507,082	$	5,552	$	282,402,437	$	(212,044,957	)	$	(38,190	)	$	70,324,842
Shares issued in lieu of interest on $1.2 million note payable extension		198,439		20		204,372		—			—			204,392
Stock-based compensation		—		—		819,955		—			—			819,955
Net Loss		—		—		—		(4,457,748	)		—			(4,457,748	)
Foreign currency translation adjustment		—		—		—		—			7,915			7,915

December 31, 2022		55,705,521	$	5,572	$	283,426,764	$	(216,502,705	)	$	(30,275	)	$	66,899,356

See accompanying notes to the unaudited condensed consolidated financial statements.

	# of Shares		Common Shares		Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income			Total
July 1, 2021		52,219,661	$	5,222	$	265,580,356		$	(90,911,805	)	$	(10,834	)	$	174,662,939
Stock-based compensation		—		—		2,727,975			—			—			2,727,975
Net Loss		—		—		—			(10,411,969	)		—			(10,411,969	)
Foreign currency translation adjustment		—		—		—			—			(3,993	)		(3,993	)
September 30, 2021		52,219,661		5,222		268,308,331			(101,323,774	)		(14,827	)		166,974,952
Stock issued pursuant to warrants exercised		100,000		10		129,990			—			—			130,000
Shares issued pursuant to LPC purchase agreement		277,340		28		3,048,311			—			—			3,048,339
Stock-Based Compensation		—		—		2,043,292			—			—			2,043,292
Shares issued for fully vested RSUs		1,266		—		9,811			—			—			9,811
Restricted shares converted to shares for services rendered		35,000		3		(3	)		—			—			—
Net Loss		—		—		—			(6,582,941	)		—			(6,582,941	)
Foreign currency translation adjustment		—		—		—			—			(3,990	)		(3,990	)
December 31, 2021		52,633,267	$	5,263	$	273,539,732		$	(107,906,715	)	$	(18,817	)	$	165,619,463

See accompanying notes to the unaudited condensed consolidated financial statements.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)


	For the Six Months Ended
	December 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(12,157,508	)	$	(16,994,910	)

ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization		57,245			63,538
Loss on extinguishment of contingent consideration liability		419,182			—
Change in contingent consideration liability		—			2,991,897
Stock based compensation expense		1,845,963			4,771,267
Amortization of discount of notes payable		149,242			148,548
Changes in assets and liabilities:
Other receivables		46			1,640
Prepaid expenses/deposits		425,233			(11,812	)
Accounts payable		3,153,358			(153,810	)
Accrued expenses		(68,554	)		(677,939	)
Other current liabilities		(18,520	)		(30,004	)
Operating leases, net		(10,832	)		(5,566	)
NET CASH USED IN OPERATING ACTIVITIES		(6,205,145	)		(9,897,151	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(23,633	)		(5,156	)
NET CASH USED IN INVESTING ACTIVITIES		(23,633	)		(5,156	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants		1,625,000			130,000
Repayment of finance agreement		(466,625	)		(227,598	)
Proceeds from LPC equity agreement		—			3,048,339
NET CASH PROVIDED BY FINANCING ACTIVITIES		1,158,375			2,950,741

Effect of exchange rates on cash		17,157			(4,937	)

NET CHANGE IN CASH		(5,053,246	)		(6,956,503	)

CASH, BEGINNING OF PERIOD		9,172,142			20,664,410

CASH, END OF PERIOD	$	4,118,896		$	13,707,907

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for:
Interest	$	30,332		$	36,462
Income Taxes	$	—		$	34
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Finance agreement entered into in exchange for prepaid assets	$	1,139,875		$	666,875
Shares in lieu of interest on $1.2 million notes payable extension	$	204,392		$	—
Common shares issued for contingent earn out liability	$	2,762,500		$	—

See accompanying notes to the unaudited condensed consolidated financial statement.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business – Enochian Biosciences Inc., (“Enochian,” or “Registrant”, and together with its subsidiaries, the “Company”, “we” or “us”) engages in the research and development of pharmaceutical and biological products for the treatment of Cancer, HIV, and HBV with the intent to manufacture said products.

Going Concern - These financial statements have been prepared on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any revenue, has incurred substantial recurring losses from continuing operations and has an accumulated deficit of $216,502,705 as of December 31, 2022. The continuation of the Company as a going concern is dependent upon (i) its ability to successfully obtain FDA approval of its product candidates, (ii) its ability to obtain any necessary debt and/or equity financing, and (iii) its ability to generate profits from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Basis of Presentation – The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at December 31, 2022, and 2021 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2022, audited financial statements. The results of operations for the periods ended December 31, 2022, and 2021 are not necessarily indicative of the operating results for the full year.

Consolidation – For the three and six months ended December 31, 2022, and 2021, the condensed consolidated financial statements include the accounts and operations of the Registrant and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.

Reclassification – Certain amounts in the prior period financial statements, have been reclassified to conform to the current presentation. For the three and six months ended December 31, 2021, we reclassified lab expenses of $193,137 and $242,330, respectively from general and administrative expenses to research and development expenses.

Accounting Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.

COVID-19 Update – The COVID-19 pandemic continues to evolve. COVID-19 may cause delays in our research activities. To date, the COVID-19 pandemic has not materially affected our operations. However, it has caused delays in the conduct of experiments due to limitations in resources and supply chain issues, in particular for those third-parties conducting experiments. There have also been increases in the cost to conduct animal studies due to staffing and other limitations.

The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate.

In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us.

Functional Currency & Foreign Currency Translation – The functional currency of Enochian Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ended December 31, 2022, and 2021. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Cash and Cash Equivalents – The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally insured amounts at December 31, 2022, and June 30, 2022, of $3,830,530 and $8,805,495, respectively.

Property and Equipment – Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets, which range from four to ten years (see Note 4.)

Intangible Assets – The Company has both definite and indefinite life intangible assets.

Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.

Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying value may not be recoverable.

Goodwill – Goodwill is not amortized but is evaluated for impairment annually as of June 30^th of each fiscal year or whenever events or changes in circumstances indicate the carrying value may not be recoverable.

Impairment of Goodwill and Indefinite Lived Intangible Assets – We test for goodwill impairment at the reporting unit level, which is one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair value, we record an impairment loss for such excess. The annual fair value analysis performed on goodwill supported that goodwill was not impaired as of June 30, 2022, and no impairment is deemed necessary as of December 31, 2022 (see Note 5.)

For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2022, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $93,253,000 during the year ended June 30, 2022. No additional impairment is deemed necessary as of December 31, 2022 (see Note 5.)

The carrying value of IPR&D and goodwill at December 31, 2022, was $61,571,000 and $11,640,000, respectively.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Impairment of Long-Lived Assets – Long-lived assets, such as property and equipment, definite and indefinite life intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.

Leases – In accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information available at the commencement date in determining the present value of the future payments.

Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 6.)

Research and Development Expenses – The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative or modified processes related to and expanding the use of the Oncology, HIV and HBV therapies and technologies for use in the prevention, treatment, amelioration of and/or therapy for Oncology, HIV and HBV. Research and development expenses for the three and six months ended December 31, 2022, amounted to $325,959 and $2,931,334, respectively. Research and development expenses for the three and six months ended December 31, 2021, amounted to $2,337,222, and $5,392,658, respectively.

Income Taxes – The Company accounts for income taxes in accordance with FASB ASC Topic 740, “Accounting for Income Taxes”, which requires an asset and liability approach for accounting for income taxes.

Loss Per Share – The Company calculates earnings/ (loss) per share in accordance with FASB ASC Topic 260, “Earnings Per Share”. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. Because of the net loss for the three and six months ended December 31, 2022, and 2021, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 4,833,436 and 7,125,894 potential shares of Common Stock excluded from the Diluted EPS calculation as of December 31, 2022, and December 31, 2021, respectively.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments – The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability (see Note 3.)

Stock Options and Restricted Share Units – The Company has granted stock options, restricted share units (“RSUs”) and warrants. The Company accounts for stock-based awards in accordance with the provisions of FASB ASC Topic 718, “Compensation - Stock Compensation”.

Stock-Based Compensation – The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation - Stock Compensation”. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the required service period, which is generally the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the three and six months ended December 31, 2022, were $819,955 and $1,845,963, respectively. Stock-based compensation costs for the vesting of the options and RSUs granted for the three and six months ended December 31, 2021, were $2,043,292 and $4,771,267, respectively. (See Note 8.)

Recently Adopted Accounting Pronouncements – Recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – GOING CONCERN

The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of approximately $4,457,748 and $12,157,508 for the three and six months ended December 31, 2022, respectively. As of December 31, 2022, the Company had cash and cash equivalents of $4,118,896 and an accumulated deficit of $216,502,705. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Management intends to raise additional funds for (a) research and development, (b) increases in personnel, and (c) the purchase of equipment, specifically to advance the Company’s potential products through the regulatory process. The Company may raise such funds from time to time through public or private sales of equity or debt securities. Such financing may not be available on acceptable terms, or at all, and the failure to raise capital when needed could materially adversely affect the Company’s growth plans and its financial condition and results of operations.

NOTE 3 — FAIR VALUE MEASUREMENTS

The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no Level 1, 2 or 3 assets, nor any Level 1, 2 or 3 liabilities measured at fair value on a recurring basis as of December 31, 2022.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

Summary of property and equipment
	Useful Life		December 31, 2022			June 30, 2022
Lab Equipment and Instruments		4-7	$	570,157		$	546,524
Leasehold Improvements		10		224,629			224,629
Furniture, Fixtures and Equipment		4-7		172,861			172,861
Total				967,647			944,014
Less Accumulated Depreciation				(411,731	)		(357,478	)
Net Property and Equipment			$	555,916		$	586,536

Depreciation expense amounted to $27,338, and $54,253 for the three and six months ended December 31, 2022, respectively, and $27,990 and $55,796 for the three and six months ended December 31, 2021, respectively.

NOTE 5 —INTANGIBLE ASSETS

At December 31, 2022, and June 30, 2022, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $42,084 and $44,268, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three and six months ended December 31, 2022, was $1,507 and $2,993, respectively. Amortization expense for the three and six months ended December 31, 2021, was $3,814 and $7,741, respectively.

At December 31, 2022, and 2021, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill.

At December 31, 2022, and June 30, 2022, definite and indefinite-life intangible assets consisted of the following:

Schedule of life intangible assets
	Useful Life	June 30, 2022			Period Change			Effect of Currency Translation			December 31, 2022
Definite Life Intangible Assets
Patents	20 Years	$	279,257		$	—		$	6,163		$	285,420
Less Accumulated Amortization			(234,989	)		(2,993	)		(5,354	)		(243,336	)
Net Definite-Life Intangible Assets		$	44,268		$	(2,993	)	$	809		$	42,084

Indefinite Life Intangible Assets
License Agreement		$	61,571,000			—			—		$	61,571,000
Goodwill			11,640,000			—			—			11,640,000
Total Indefinite Life Intangible Assets		$	73,211,000			—			—		$	73,211,000

Expected future amortization expense is as follows:


Year ending June 30,
	2023	$	8,883
	2024		11,067
	2025		11,067
	2026		11,067
	Total	$	42,084

During February 2018, the Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment.

Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment indicated that the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value, due to the sublicensing of ENOB HV-01, which required a different valuation approach and changes in other factors impacting the fair value of the asset. Therefore, an impairment adjustment of $93,253,000 was recorded in the year ended June 30, 2022. No additional impairment is deemed necessary as of December 31, 2022.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 — LEASES

Operating Leases — On November 13, 2017, the Company entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”), pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year, and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized.

On June 19, 2018, the Company entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Company entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease expense for the term of the lease is $20,050. The Company subleased the space as of June 25, 2022 (see subsection below “Sublease Agreement” for details.)

The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:

Expected lease term — The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s lease has a remaining lease term of 56 months. As of December 31, 2022, the weighted-average remaining term is 4.67 years.

Incremental borrowing rate — The Company’s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of December 31, 2022, the weighted-average discount rate is 4.03%.

Lease and non-lease components — In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in the period in which the costs are incurred.

Below are the lease commitments for the next 5 years:

Lease commitments
Year Ending June 30^th	Lease Expense
2023	$	120,002
2024		246,004
2025		253,384
2026		260,985
2027		313,836
Less imputed interest		(109,538	)
Total	$	1,084,673

Sublease Agreement

On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.

In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sales-type or direct financing lease.

The Company will recognize operating income from the sublease on a straight-line basis in its statements of operations over the sublease term.

During the three and six months ended December 31, 2022 and 2021, the net operating lease expenses were as follows:


	For the Three Months Ended					For the Six Months Ended
	December 31,					December 31,
	2022			2021		2022			2021

Operating Lease Expense	$	96,730		$	84,113	$	140,660		$	168,196
Sub lease Income		(53,310	)		—		(106,620	)		—

Total Net Lease Expense	$	43,420		$	84,113	$	34,040		$	168,196

Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2022, amounted to $43,420 and $34,040, respectively. Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2021, amounted to $84,113 and $168,196, respectively.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 — NOTES PAYABLE

Convertible Notes Payable — On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to Paseco APS (the “Holder”), a Danish limited company and an existing stockholder of the Company each with a face value amount of $600,000, convertible into shares of Common Stock, $0.0001 par value per share. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023. Interest on the Convertible Notes commenced accruing on the date of issuance at six percent (6%) per annum, computed on the basis of twelve 30-day months, and is compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as of such compound date. The interest was payable in cash on a semi-annual basis.

The holder of the Convertible Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid principal and all unpaid interest into shares of the Company’s Common Stock. The conversion price was equal to $12.00 per share of Common Stock. The Holder did not exercise the conversion feature that expired on February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. All proceeds received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes balance as of December 31, 2022 and 2021, was $1,200,000.

Effective December 30, 2022 (the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February 28, 2024, and the interest was increased to twelve percent (12%) per annum, which was prepaid by the Company in full on the date of amendment through the issuance of 198,439 shares of the Company’s Common Stock which is comprised of 29,419 shares for accrued interest up to the Effective Date and 169,020 shares related to the prepayment of interest through the extension date of the Amended and Restated Secured Notes using the closing market price on that date, of $1.03. The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the “Security Agreement”). The Company evaluated the Secured Notes and conversion feature to determine the appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480-Distinguising Liabilities from Equity, the Company determined that the Secured Notes embody an obligation that may require the Company to settle with the issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a fixed monetary amount $1,200,000 known at inception. Accordingly, the Company recorded the Secured Note as share settled debt. The total value of the shares issued were $204,392 which included $174,090 as prepaid interest and $30,302 for accrued interest as of December 30, 2022.

As of December 31, 2022 and 2021, the Company recorded accrued interest in the amount of zero 0 and $24,181, which is included in accrued expenses. For the three and six months ended December 31, 2022 the interest expense related to the Convertible Notes amounted to $18,272 and $36,453 respectively. For the three and six months ended December 31, 2021 the interest expense related to the Convertible Notes amounted to $18,181 and $36,453 respectively.

Note Payable — On March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $5,000,000 (the “Promissory Note”) to the Holder. The principal amount of the Promissory Note was originally payable on November 30, 2021 (the “Maturity Date”). The Promissory Note bore interest at a fixed rate of 6% per annum, computed based on the number of days between the Issuance Date and the Maturity Date, which was prepaid by the Company in full on the Issuance Date through the issuance of 188,485 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $501,370. The Company evaluated the Unsecured Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount of $493,192, which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest method. The discount of $493,192 will be accreted over the life of the Promissory Note.

On February 11, 2021, the Company entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6% per annum, which was prepaid by the Company in full on the date of the amendment through the issuance of 74,054 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $298,178.

On May 17, 2022, the Company entered into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 and increased the interest rate from 6% to 12% per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022 until May 30, 2023 on the date of the amendment through the issuance of 47,115 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $299,178. All other accrued interest payable from May 30, 2023 to the Maturity Date shall be payable by the Company on May 30, 2023, at the option of the Holder either (i) in cash or (ii) in non-assessable shares of the Company’s Common Stock, valued at the closing sale price of the Common Stock of the Nasdaq Capital Market on May 30, 2023.

Effective December 30, 2022, the Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under the Promissory Note were secured by the Security Agreement. To secure the Company’s obligations under each of the Amended and Restated Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral.

For the three and six months ended December 31, 2022, discount amortization of $74,621 and $149,242 was charged to interest expense. For the three and six months ended December 31, 2021, discount amortization of $74,274 and $148,548 was charged to interest expense. The Promissory Note balance, net of discount at December 31, 2022 is $4,726,390.

Finance Agreement — On November 30, 2022, the Company entered into a premium finance agreement (the “Agreement”) related to insurance, which resulted into a prepaid expense with a principal amount of $1,139,875 at 6.69% interest per annum. The repayment of the Agreement will be made in nine equal monthly installments of $96,220. For the three and six months ended December 31, 2022 and 2021, the Company made repayments of $466,625 and $227,598 respectively.

For the three and six months ended December 31, 2022, the Company recorded total interest expense in the amount of $2,782. This amount is reflected in other income and expenses.

Total interest expense recorded for the three and six months ended December 31, 2022, was $92,892 and $188,477, respectively. Interest expense recorded for the three and six months ended December 31, 2021, was $93,382 and $183,121, respectively.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — STOCKHOLDERS’ EQUITY

Preferred Stock —The Company has 10,000,000 authorized shares of Preferred Stock, par value $0.0001 per share. At December 31, 2022, and June 30, 2022, there were zero 0 shares issued and outstanding.

Common Stock —The Company has 100,000,000 authorized shares of Common Stock, par value $0.0001 per share. At December 31, 2022, and June 30, 2022, there were 55,705,521 and 53,007,082 shares issued and outstanding, respectively.

Voting — Holders of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.

Dividends — Holders of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available.

Liquidation Rights — In the event of any liquidation, dissolution or winding up of affairs of the Company, after payment of all debts and liabilities, the holders of Common Stock will be entitled to share ratably in the distribution of any of the remaining assets.

Purchase Agreement with Lincoln Park Capital

On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $20,000,000 of shares of Common Stock from time to time through August 1, 2023.

In consideration for entering into the Purchase Agreement, we issued 139,567 shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.

During the six months ended December 31, 2022 and 2021, we did not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement. As of October 17, 2022, we no longer have access to this Purchase Agreement as we are no longer able to use the registration statement on Form S-3 that registered the shares issuable to Lincoln Park under the Purchase Agreement.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — STOCKHOLDERS’ EQUITY (Continued)

Common Stock Issuances

On July 14, 2022, certain of our warrant holders exercised warrants to purchase 1,250,000 shares of Common Stock for total proceeds to the Company of $1,625,000, with corresponding earn-out distribution of the same number of shares in connection with the acquisition of Enochian BioPharma, Inc. This non-cash earn-out distribution impacted stockholders’ equity in the amount of $2,762,500 based on the share price on July 14, 2022 of $2.21. In the three and six months ended December 31, 2022 there were 198,439 and 2,698,439 shares of Common Stock issued, respectively. The Company recorded a loss on extinguishment of contingent consideration liability of $419,182 during the six months ended December 31, 2022 which reflects the difference between the fair value of the shares and the contingent consideration liability at the time of extinguishment. As of December 31, 2022, all outstanding warrants have been exercised and there is no further contingent consideration liability balance remaining as of the end of this period.

Acquisition of Enochian Biopharma Inc. / Contingently issuable shares — On February 16, 2018, the acquisition of Enochian Biopharma was completed. As part of the acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants, which were outstanding at closing. As of December 31, 2022, no further Contingent Shares are issuable.

Acquisition of Enochian Denmark — At December 31, 2022, and June 30, 2022, the Company maintained a reserve of 17,414 shares of Common Stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”), all of which are reflected as issued and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian Denmark held by non-consenting shareholders of Enochian Denmark on both December 31, 2022, and June 30, 2022, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been 167,639 shares of Common Stock issued to non-consenting shareholders of Enochian Denmark as of December 31, 2022. During the three and six months ended December 31, 2022, the Company issued zero 0 shares of Common Stock to such non-consenting shareholders of Enochian Denmark.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — STOCKHOLDERS’ EQUITY (Continued)

Stock-based Compensation

The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended December 31, 2022:


	Enochian Biosciences Inc.
Expected term (in years)		5.3 – 6.5
Volatility		84.66%-90.75%
Risk free interest rate		2.70%-4.14%
Dividend yield		0%

The Company recognized stock-based compensation expense related to the options of $819,955 and $1,845,963 for the three and six months ended December 31, 2022, respectively. The Company recognized stock-based compensation expense related to the options of $2,043,292 and $4,771,267 for the three and six months ended December 31, 2021, respectively. At December 31, 2022, the Company had approximately $4,990,165 of unrecognized compensation cost related to non-vested options.

Plan Options

On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.

On October 30, 2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.

Pursuant to the 2019 Plan, the Company granted options to purchase 178,000 shares of Common Stock to employees with a three-year vesting period during the three and six months ended December 31, 2022, respectively. For the three and six months ended December 31, 2021, the Company granted options to purchase 120,900 and 3,130,200 shares of Common Stock to employees with a three-year vesting period, respectively.

During the three and six months ended December 31, 2022, the Company granted options to purchase zero 0 and 184,800 shares of Common stock to employees with a six-month vesting period, respectively. For the three and six months ended December 31, 2021, the Company did not grant options to purchase shares of Common Stock to employees with a six-month vesting period.

During the three and six months ended December 31, 2022, the Company granted options to purchase zero 0 and 73,200 shares of Common stock to employees with a one-year vesting period, respectively. For the three and six months ended December 31, 2021, the Company did not grant options to purchase shares of Common Stock to employees with a one-year vesting period.

During the three and six months ended December 31, 2022, the Company granted options to purchase 159,959 and 210,917 shares of Common Stock, to the Board of Directors and Scientific Advisory Board Members with a one-year vesting period, respectively. For the three and six months ended December 31, 2021, the Company granted options to purchase 36,727 and 63,462 shares of Common Stock to members of the Board of Directors and Scientific Advisory Board with a one-year vesting period, respectively.

During the three and six months ended December 31, 2022, the Company did not grant options to purchase shares of Common stock for consulting services. For the three and six months ended December 2021, the Company granted options to purchase 21,979 shares of Common Stock with immediate vesting, issued options to purchase 17,500 shares of Common Stock with a one-year vesting period, and issued options to purchase 60,000 shares of Common Stock with a three-year vesting period for consulting services.

All of the above options are exercisable at the market price of the Company’s Common Stock on the date of the grant.

To date the Company has granted options under the 2014 Plan and 2019 Plan (“Plan Options”) to purchase 5,475,559 shares of Common Stock. At December 31, 2022 the Company has 2,310,289 options available to be issued under the 2019 Plan.

ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — STOCKHOLDERS’ EQUITY (Continued)

A summary of the status of the Plan Options outstanding at December 31, 2022, is presented below :

Summary of stock options outstanding
	Options Outstanding								Options Exercisable
	Exercise Price Ranges		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price
	$	1.00–4.50		860,273		8.97	$	2.40		217,064		6.83	$	3.21
	$	4.51–6.50		3,169,769		8.20	$	4.83		1,153,876		7.59	$	5.26
	$	6.51–8.00		803,393		7.70	$	8.02		604,414		7.24	$	7.94
Total				4,833,436		8.26	$	4.93		1,975,354		7.40	$	5.85

A summary of the status of the Plan Options at December 31, 2022, and changes since July 1, 2022, are presented below:

Summary of stock option activity
	Shares		Weighted Average Exercise Price		Average Remaining Life		Weighted Average Intrinsic Value

Outstanding at beginning of period		4,307,820	$	5.37		8.55	$	—
Granted		646,917	$	2.07
Exercised		—	$	—
Forfeited		(

SEC Form 10-Q filed by Enochian Biosciences Inc.